Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays ...

Moderna Inc. fell Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market.

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

The company said, “Over the near term, Moderna (MRNA) will continue to build a large seasonal vaccine franchise targeting at-risk populations and ...

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...